Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015 May;35(5):1046-7.
doi: 10.1161/ATVBAHA.115.305395.

Wnting out ocular neovascularization: using nanoparticle delivery of very-low density lipoprotein receptor extracellular domain as Wnt pathway inhibitor in the retina

Julia V Busik  1 , Maria B Grant  2
Affiliations
Editorial

Wnting out ocular neovascularization: using nanoparticle delivery of very-low density lipoprotein receptor extracellular domain as Wnt pathway inhibitor in the retina

Julia V Busik et al. Arterioscler Thromb Vasc Biol. 2015 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Inhibition of Wnt signaling pathway by nanoparticle delivery of VLDLRN-terminal ectodomain (VLN) controls VEGF production and neovascularization in the retina
Binding of Wnt ligands to frizzled and low-density lipoprotein receptor-related protein 5/6 (LRP5/6) complex leads to attenuation of phosphorylation and stabilization of cytoplasmic β-catenin. β-catenin is then translocated into the nucleus, where it associates with and activates T cell factor (TCF). TCF activation leads to transcription of Wnt target genes including VEGF (left). Nanoparticle delivery of VLN inhibits LRP6 leading to destabilization of β-catenin, inactivation of TCF, and inhibition of transcription of Wnt target genes including VEGF (right).
See this image and copyright information in PMC

Comment on

References

    1. Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. The Cochrane database of systematic reviews. 2014;10:CD007419. - PubMed
    1. Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. The Cochrane database of systematic reviews. 2012;12:CD007419. - PubMed
    1. Parravano M, Menchini F, Virgili G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. The Cochrane database of systematic reviews. 2009;(4):CD007419. - PubMed
    1. Gragoudas ES, Adamis AP, Cunningham ET, Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. The New England journal of medicine. 2004;351(27):2805–2816. - PubMed
    1. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. The British journal of ophthalmology. 2007;91(10):1318–1322. - PMC - PubMed